The present invention relates to a method for treating glioblastoma multiforme including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Boswella sacra, Commiphora molmol, Angelica sinensis, Ligusticum striatum, Rehmannia glutinosa, Paeonia veitchii, Prunus persica, and Carthamus tinctorius.

The present invention relates to a method for treating glioblastoma multiforme including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Boswella sacra, Commiphora molmol, Angelica sinensis, Ligusticum striatum, Rehmannia glutinosa, Paeonia veitchii, Prunus persica, and Carthamus tinctorius.

The application discloses a traditional Chinese medicine composition for treating of type 2 diabetes, comprising the following raw materials: wild Descolor Cinquefoil Herb, wild Rhizoma imperatae, wild Root and Rhizome of Japanese Climbing Fern, Ginseng leaf (over 7 years), wild Rough Melic, wild Vitex negundo L., Morus alba L., green tea, wild auricularia, corn silk, dandelion root. The traditional Chinese medicine composition of the application is suitable for patients with type 2 diabetes and complications of type 2 diabetes, which has no adverse reactions and stable curative effect.

The application discloses a traditional Chinese medicine composition for treating of type 2 diabetes, comprising the following raw materials: wild Descolor Cinquefoil Herb, wild Rhizoma imperatae, wild Root and Rhizome of Japanese Climbing Fern, Ginseng leaf (over 7 years), wild Rough Melic, wild Vitex negundo L., Morus alba L., green tea, wild auricularia, corn silk, dandelion root. The traditional Chinese medicine composition of the application is suitable for patients with type 2 diabetes and complications of type 2 diabetes, which has no adverse reactions and stable curative effect.

A eutectic extraction solvent for extracting plant (e.g. vegetable) and/or animal and/or prokaryotic biological material, wherein the solvent is a clear, stable and fluid mixture comprising: (a) betaine or a hydrated form of betaine; (b) at least one hydrogen bond donor compound selected from the group consisting of polyols and organic acids; and (c) water
with the proviso that the eutectic extraction solvent does not contain any exogenous sugar and/or amine salt and/or anion.

A eutectic extraction solvent for extracting plant (e.g. vegetable) and/or animal and/or prokaryotic biological material, wherein the solvent is a clear, stable and fluid mixture comprising: (a) betaine or a hydrated form of betaine; (b) at least one hydrogen bond donor compound selected from the group consisting of polyols and organic acids; and (c) water
with the proviso that the eutectic extraction solvent does not contain any exogenous sugar and/or amine salt and/or anion.

The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of β-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.

The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of β-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.

A confection may include one or more skin protective ingredients, a thickening agent, and a sweetening agent. The one or more skin protective ingredients may include Polypodium leucotomos extract, astaxanthin, Pinus pinaster, lycopene, lutein, and/or zeaxanthin. In some embodiments, the confection may be formulated as a gummy, chewable, or candy, and may be taken orally on a regular basis (e.g., daily) to treat and/or prevent one or more skin conditions.

A confection may include one or more skin protective ingredients, a thickening agent, and a sweetening agent. The one or more skin protective ingredients may include Polypodium leucotomos extract, astaxanthin, Pinus pinaster, lycopene, lutein, and/or zeaxanthin. In some embodiments, the confection may be formulated as a gummy, chewable, or candy, and may be taken orally on a regular basis (e.g., daily) to treat and/or prevent one or more skin conditions.